Altimmune, Inc.
ALTNASDAQHealthcare● Active
$2.72
+$0.01(+0.21%)
Market Cap$239671524
P/E Ratio—
52W High$7.73
52W Low$2.56
Altimmune, Inc. (ALT) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · ALT · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.04M | $0.02M | $0.43M | ($0.07M) | $4.41M |
| Cost of Revenue | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Gross Profit | $0.04M | $0.02M | $0.43M | ($0.07M) | $4.41M |
| Gross Margin %(computed) | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| Operating Expenses | |||||
| R&D Expenses | $66.43M | $82.23M | $65.80M | $70.54M | $74.54M |
| G&A Expenses | $28.10M | $20.97M | $18.14M | $17.13M | $15.41M |
| Total Operating Expenses | $94.53M | $103.19M | $96.36M | $87.67M | $101.32M |
| Operating Income | ($94.49M) | ($103.17M) | ($95.93M) | ($87.74M) | ($96.91M) |
| Operating Margin %(computed) | — | — | — | — | — |
| Interest Income | $7.54M | $8.07M | $7.35M | $2.87M | $0.20M |
| Interest Expense | $1.64M | $0.01M | $0.04M | $0.01M | $0.01M |
| Income Before Tax | ($88.77M) | ($95.06M) | ($88.45M) | ($84.91M) | ($97.09M) |
| Income Tax Expense | ($0.68M) | $0.00M | $0.00M | ($0.20M) | $0.00M |
| Net Income | ($88.09M) | ($95.06M) | ($88.45M) | ($84.71M) | ($97.09M) |
| Net Margin %(computed) | — | — | — | — | — |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-1.00 | $-1.34 | $-1.66 | $-1.81 | $-2.35 |
| Wtd Avg Shares | 88.10M | 71.00M | 53.25M | 46.93M | 41.28M |
| EBITDA | ($87.03M) | ($94.81M) | ($87.94M) | ($84.41M) | ($96.53M) |
| EBITDA Margin %(computed) | — | — | — | — | — |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · USD · M
Explore more Altimmune, Inc. data
About Altimmune, Inc. (ALT) Income Statement
Altimmune, Inc. (ALT) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, ALT reported revenue of $0.00B, gross profit of $0.00B (gross margin 100.00%), and net income of ($0.09B) — a net profit margin of -214860.98%.
Frequently asked questions
ALT · 4 questionsAltimmune, Inc. (ALT) reported revenue of $0.00B for 2025, up 105.0% year-over-year.
ALT revenueALT salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08